Ku蛋白在膀胱癌组织中表达的免疫组织化学研究

Immunohistochemical study on the expression of Ku proteins in carcinoma of bladder

目的:研究Ku蛋白表达与膀胱癌发生、进展的关系。方法:应用SP法对98例行经尿道膀胱肿瘤电切术(TURBT)、根治性膀胱切除术的膀胱组织标本进行免疫组织化学染色;应用形态计量学分析方法结合临床相关病理资料分析Ku蛋白表达与膀胱癌肿瘤相关指标的关系。结果:98例膀胱癌组织中Ku蛋白总阳性表达数为79例(80.61%)。67例非肌层浸润性膀胱癌组织中Ku蛋白阳性表达数为60例(89.55%),31例肌层浸润性膀胱癌中Ku蛋白阳性表达数为19例(61.29%),两者差异有显著统计学意义(P<0.01)。图像分析结果:肌层浸润性膀胱癌组(2 453.05±221.24)和非肌层浸润性膀胱癌组(4 349.41±307.20)之间积分光密度的差异有显著统计学意义(P<0.01)。肿瘤组织(3 605.67±1 024.80)与癌旁组织(396.84±60.24)之间积分光密度的差异度亦有显著统计学意义(P<0.01)。结论:Ku蛋白可能在膀胱癌进展的过程中发挥着重要作用。早期Ku蛋白表达增加是膀胱癌发生的一个重要因素。晚期Ku蛋白表达下调与膀胱癌的侵袭性密切相关。

Objective： To study the correlation between the expression of Ku proteins and the development and progression of carcinoma of bladder. Method： Ku proteins expression levels of 98 cases of samples which were ob- tained surgically by transurethral resection of bladder （TURBT） or radical cystectomy were examined by immuno- histochemistry. The results were analyzed by morphometric analysis combined with the clinicopathologic data. Re- sult： Of the 98 cases, 79 cases were positive for the expression of Ku proteins （80.61% ）. The percentage of posi- tive expression of Ku proteins in the non muscle-invasive bladder cancer group （89.55%, 60/67） was significantly higher （P〈0.01） than that of the musclednvasive bladder cancer group （61.29 %, 19/31）. Morpbometry demon- strated that mean optical density levels of Ku proteins of the non muscle-invasive bladder cancer group （4 349.41 ±307.20） was significantly higher （P〈0.01） than that of the muscle-invasive bladder cancer group （2 453.05±221.24）. There was a significant difference （P〈0.01） between the carcinoma （3 605.67± 1 024.80） and the bladder tissues adjacent to the carcinoma （396.84±60.24）. Conclusion： Ku proteins may play an important role in the progressive processes. The increasing expression of Ku proteins may be one important mechanism of earlier phases of bladder cancer genesis. The down-regulating expression of Ku proteins is closely related with the invasion of carcinoma of bladder.